Investigation of the Impact of <i>CYP3A5</i> Polymorphism on Drug–Drug Interaction between Tacrolimus and Schisantherin A/Schisandrin A Based on Physiologically-Based Pharmacokinetic Modeling

Investigation of the Impact of <i>CYP3A5</i> Polymorphism on Drug–Drug Interaction between Tacrolimus and Schisantherin A/Schisandrin A Based on Physiologically-Based Pharmacokinetic Modeling

Wuzhi capsule (WZC) is commonly prescribed with tacrolimus in China to ease drug-induced hepatotoxicity. Two abundant active ingredients, schisantherin A (STA) and schisandrin A (SIA) are known to inhibit CYP3A enzymes and increase tacrolimus’s exposure. Our previous study has quantitatively demonst...

Full description

Bibliographic Details
Main Authors: Qingfeng He, Fengjiao Bu, Hongyan Zhang, Qizhen Wang, Zhijia Tang, Jing Yuan, Hai-Shu Lin, Xiaoqiang Xiang
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:Pharmaceuticals
Subjects:
physiologically-based pharmacokinetic (PBPK)
Wuzhi capsule (WZC)
tacrolimus
<i>CYP3A5</i> polymorphism
drug–drug interaction (DDI)
schisantherin A (STA)
Online Access:https://www.mdpi.com/1424-8247/14/3/198

Similar Items

Similar Items